Harnessing Integrative Omics to Facilitate Molecular Imaging of the Human Epidermal Growth Factor Receptor Family for Precision Medicine

Cancer is a growing problem worldwide. The cause of death in cancer patients is often due to treatment-resistant metastatic disease. Many molecularly targeted anticancer drugs have been developed against 'oncogenic driver' pathways. However, these treatments are usually only effective in properly selected patients. Resistance to molecularly targeted drugs through selective pressure on acquired mutations or molecular rewiring can hinder their effectiveness. This review summarizes how molecular imaging techniques can potentially facilitate the optimal implementation of targeted agents. Using the human epidermal growth factor receptor (HER) family as a model in (pre)clinical studies, we illustrate how molecular imaging may be employed to characterize whole body target expression as well as monitor drug effectiveness and the emergence of tumor resistance. We further discuss how an integrative omics discovery platform could guide the selection of 'effect sensors' - new molecular imaging targets - which are dynamic markers that indicate treatment effectiveness or resistance.

• Publication year

  2017

• Venue

  Theranostics

• Publication date

  2017-05-27

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.7150/thno.17934PMID 28638489PMCID 5479290
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Functional Genomic mRNA Profiling of Colorectal Adenomas: Identification and in vivo Validation of CD44 and Splice Variant CD44v6 as Molecular Imaging Targets

  2017cited by this paper
• Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer

  2017cited by this paper
• Associations Between Somatic Mutations and Metabolic Imaging Phenotypes in Non–Small Cell Lung Cancer

  2017influential reference
• 89Zr-Lumretuzumab PET Imaging before and during HER3 Antibody Lumretuzumab Treatment in Patients with Solid Tumors

  2017cited by this paper
• Extracellular domain shedding influences specific tumor uptake and organ distribution of the EGFR PET tracer 89Zr-imgatuzumab

  2016cited by this paper
• Molecular Fluorescence Endoscopy Targeting Vascular Endothelial Growth Factor A for Improved Colorectal Polyp Detection

  2016cited by this paper
• Unsolicited findings of next-generation sequencing for tumor analysis within a Dutch consortium: clinical daily practice reconsidered

  2016cited by this paper
• Differential Receptor Tyrosine Kinase PET Imaging for Therapeutic Guidance

  2016influential reference
• Phase 1 Evaluation of [64Cu]DOTA-Patritumab to Assess Dosimetry, Apparent Receptor Occupancy, and Safety in Subjects with Advanced Solid Tumors

  2016cited by this paper
• 89Zr-lumretuzumab PET imaging before and during HER3 antibody lumretuzumab treatment of solid tumor patients.

  2016cited by this paper
• Biomarker development in the precision medicine era: lung cancer as a case study

  2016cited by this paper
• Imaging Diagnostic and Therapeutic Targets: Human Epidermal Growth Factor Receptor 2

  2016cited by this paper
• Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial.

  2016cited by this paper
• Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma

  2016cited by this paper
• Proteogenomics connects somatic mutations to signaling in breast cancer

  2016influential reference
• Radiomic Features Are Associated With EGFR Mutation Status in Lung Adenocarcinomas.

  2016cited by this paper
• 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.

  2016cited by this paper
• Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance

  2016cited by this paper
• A gradient-loadable (64)Cu-chelator for quantifying tumor deposition kinetics of nanoliposomal therapeutics by positron emission tomography.

  2015cited by this paper
• Identifying erlotinib-sensitive non-small cell lung carcinoma tumors in mice using [11C]erlotinib PET

  2015cited by this paper
• A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [11C]erlotinib and [18F]afatinib in lung cancer-bearing mice

  2015cited by this paper
• Identifying novel targets of oncogenic EGF receptor signaling in lung cancer through global phosphoproteomics

  2015cited by this paper
• Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors.

  2015cited by this paper
• Imaging the distribution of an antibody-drug conjugate constituent targeting mesothelin with 89Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts

  2015cited by this paper
• Clonal status of actionable driver events and the timing of mutational processes in cancer evolution

  2015cited by this paper
• Mucolytic Agents Can Enhance HER2 Receptor Accessibility for [89Zr]Trastuzumab, Improving HER2 Imaging in a Mucin-Overexpressing Breast Cancer Xenograft Mouse Model

  2015cited by this paper
• A Multi-Method Approach for Proteomic Network Inference in 11 Human Cancers

  2015cited by this paper
• Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

  2015cited by this paper
• Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials.

  2015cited by this paper
• Affibody-mediated PET imaging of HER3 expression in malignant tumours

  2015cited by this paper
• ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody–Drug Conjugate Treatment

  2015influential reference
• Molecular Imaging As a Tool for Drug Development and Trial Design.

  2015cited by this paper
• In Vivo Fluorescence Immunohistochemistry: Localization of Fluorescently Labeled Cetuximab in Squamous Cell Carcinomas

  2015cited by this paper
• Quantitative mass spectrometry of posttranslational modifications: Keys to confidence

  2015cited by this paper
• Near Infrared Photoimmunotherapy Targeting EGFR Positive Triple Negative Breast Cancer: Optimizing the Conjugate-Light Regimen

  2015cited by this paper
• 89Zr-cetuximab PET imaging in patients with advanced colorectal cancer

  2015cited by this paper
• Whole-body organ-level and kidney micro-dosimetric evaluations of 64Cu-loaded HER2/ErbB2-targeted liposomal doxorubicin (64Cu-MM-302) in rodents and primates

  2015cited by this paper
• Retargeted human avidin-CAR T cells for adoptive immunotherapy of EGFRvIII expressing gliomas and their evaluation via optical imaging

  2015cited by this paper
• Radiopharmaceuticals as probes to characterize tumour tissue

  2015cited by this paper
• Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.

  2015cited by this paper
• Safety and Tumor Specificity of Cetuximab-IRDye800 for Surgical Navigation in Head and Neck Cancer

  2015cited by this paper
• New EuroGentest/ESHG guidelines and a new clinical utility gene card format for NGS-based testing

  2015cited by this paper
• Quantitative in vivo cell-surface receptor imaging in oncology: kinetic modeling and paired-agent principles from nuclear medicine and optical imaging

  2015cited by this paper
• PET imaging of DNA damage using 89Zr-labelled anti-γH2AX-TAT immunoconjugates

  2015cited by this paper
• Radiomics: Images Are More than Pictures, They Are Data

  2015cited by this paper
• Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.

  2015cited by this paper
• Roles of c-Met and RON kinases in tumor progression and their potential as therapeutic targets

  2015cited by this paper
• Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial.

  2015cited by this paper
• Comparative evaluation of 111In-labeled NOTA‑conjugated affibody molecules for visualization of HER3 expression in malignant tumors.

  2015cited by this paper
• Evaluation of 89Zr-pertuzumab in Breast Cancer Xenografts

  2014cited by this paper
• Thirty years of research on met receptor to move a biomarker from bench to bedside.

  2014cited by this paper
• Visualising dual downregulation of insulin-like growth factor receptor-1 and vascular endothelial growth factor-A by heat shock protein 90 inhibition effect in triple negative breast cancer.

  2014cited by this paper
• ImmunoPET and biodistribution with human epidermal growth factor receptor 3 targeting antibody 89Zr-RG7116

  2014cited by this paper
• Noninvasive Image Texture Analysis Differentiates K-ras Mutation from Pan-Wildtype NSCLC and Is Prognostic

  2014cited by this paper
• Intraoperative fluorescence delineation of head and neck cancer with a fluorescent Anti‐epidermal growth factor receptor nanobody

  2014cited by this paper
• 89Zr-trastuzumab and 89Zr-bevacizumab PET to Evaluate the Effect of the HSP90 Inhibitor NVP-AUY922 in Metastatic Breast Cancer Patients

  2014cited by this paper
• First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the 111In-ABY-025 Affibody Molecule

  2014cited by this paper
• Evaluation of reverse phase protein array (RPPA)-based pathway-activation profiling in 84 non-small cell lung cancer (NSCLC) cell lines as platform for cancer proteomics and biomarker discovery.

  2014cited by this paper
• Proteogenomic characterization of human colon and rectal cancer

  2014influential reference
• Development of a HER3 PET probe for breast cancer imaging

  2014cited by this paper
• Radiomics in PET: principles and applications

  2014cited by this paper
• Imaging DNA Damage Allows Detection of Preneoplasia in the BALB-neuT Model of Breast Cancer

  2014cited by this paper
• ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.

  2014influential reference
• A comparative study of affibody, panitumumab, and EGF for near-infrared fluorescence imaging of EGFR- and EGFRvIII-expressing tumors

  2014cited by this paper
• Associate editor: B. TeicherHER3, serious partner in crime: Therapeutic approaches and potential biomarkers for effect of HER3-targeting

  2014cited by this paper
• Use of monoclonal antibody-IRDye800CW bioconjugates in the resection of breast cancer.

  2014cited by this paper
• Imaging EGFR and HER2 by PET and SPECT: A Review

  2014cited by this paper
• Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations.

  2014cited by this paper
• Imaging of HER3-expressing xenografts in mice using a 99mTc(CO)3-HEHEHE-ZHER3:08699 affibody molecule

  2014cited by this paper
• Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials

  2014cited by this paper
• Design, Synthesis, and Validation of Axl-Targeted Monoclonal Antibody Probe for microPET Imaging in Human Lung Cancer Xenograft

  2014cited by this paper
• Axl-Targeted Cancer Imaging with Humanized Antibody h173

  2014cited by this paper
• HSP90 inhibitor AUY922 abrogates up‐regulation of RTKs by mTOR inhibitor AZD8055 and potentiates its antiproliferative activity in human breast cancer

  2014cited by this paper
• Everolimus Reduces 89Zr-Bevacizumab Tumor Uptake in Patients with Neuroendocrine Tumors

  2014cited by this paper
• Antagonism of EGFR and HER3 Enhances the Response to Inhibitors of the PI3K-Akt Pathway in Triple-Negative Breast Cancer

  2014cited by this paper
• Molecular imaging to guide clinical decisions on targeted treatment of solid tumors

  2014cited by this paper
• Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.

  2013cited by this paper
• Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake.

  2013cited by this paper
• Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.

  2013cited by this paper
• Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy

  2013cited by this paper
• Quantitative analysis of [11C]-erlotinib PET demonstrates specific binding for activating mutations of the EGFR kinase domain.

  2013cited by this paper
• Monitoring Afatinib Treatment in HER2-Positive Gastric Cancer with 18F-FDG and 89Zr-Trastuzumab PET

  2013cited by this paper
• Cancer heterogeneity: implications for targeted therapeutics

  2013cited by this paper
• Mutational landscape and significance across 12 major cancer types

  2013cited by this paper
• An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models

  2013cited by this paper
• Imaging of Epidermal Growth Factor Receptor Expression in Head and Neck Cancer with SPECT/CT and 111In-Labeled Cetuximab-F(ab′)2

  2013cited by this paper
• Development of a 5-plex SILAC Method Tuned for the Quantitation of Tyrosine Phosphorylation Dynamics

  2013cited by this paper
• TCPA: a resource for cancer functional proteomics data

  2013cited by this paper
• The Cancer Genome Atlas Pan-Cancer analysis project

  2013cited by this paper
• Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway.

  2013cited by this paper
• Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges

  2013cited by this paper
• Comprehensive molecular portraits of human breast tumours

  2013cited by this paper
• PET imaging of oestrogen receptors in patients with breast cancer.

  2013cited by this paper
• Profiling phospho-signaling networks in breast cancer using reverse-phase protein arrays

  2013cited by this paper
• The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered

  2013cited by this paper
• Axl Mediates Acquired Resistance of Head and Neck Cancer Cells to the Epidermal Growth Factor Receptor Inhibitor Erlotinib

  2013cited by this paper
• Ten Years of Standardizing Proteomic Data: A Report on the HUPO‐PSI Spring Workshop

  2012cited by this paper
• The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

  2012cited by this paper
• c-Src Activation Mediates Erlotinib Resistance in Head and Neck Cancer by Stimulating c-Met

  2012cited by this paper
• Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

  2012cited by this paper

• Prostate-Specific Membrane Antigen (PSMA) PET-CT: Revolutionizing Staging, Restaging, and Treatment Response Assessment

  2025cites this paper
• The interdiscipline rendezvous of aptamers and radionuclides: Advances, challenges and prospects

  2025cites this paper
• The Impact of Bevacizumab and miR200c on EMT and EGFR-TKI Resistance in EGFR-Mutant Lung Cancer Organoids

  2024cites this paper
• [Covalently conjugated DNA aptamer with doxorubicin as in vitro model for effective targeted drug delivery to human glioblastoma tumor cells].

  2024cites this paper
• EGFR-Targeted ImmunoPET of UMUC3 Orthotopic Bladder Tumors

  2022cites this paper
• An Integrative Transcriptomic Analysis Reveals EGFR Exon-19 E746-A750 Fragment Deletion Regulated miRNA, circRNA, mRNA and lncRNA Networks in Lung Carcinoma

  2022cites this paper
• The Radiolabeled HER3 Targeting Molecules for Tumor Imaging

  2021cites this paper
• Radiochemistry, Production Processes, Labeling Methods, and ImmunoPET Imaging Pharmaceuticals of Iodine-124

  2021cites this paper
• ImmunoPET: Concept, Design, and Applications.

  2020cites this paper
• Preclinical evaluation and molecular imaging of HER family dynamics to guide cancer therapy

  2019cites this paper
• PET imaging of EGFR expression using an 18F-labeled RNA aptamer

  2018cites this paper
• Quantitative proteomics analysis identifies MUC1 as an effect sensor of EGFR inhibition

  2018cites this paper
• Clinical Potential of Human Epidermal Growth Factor Receptor 2 and Human Epidermal Growth Factor Receptor 3 Imaging in Breast Cancer.

  2018cites this paper
• Imaging of human epidermal growth factor receptors for patient selection and response monitoring - From PET imaging and beyond.

  2018cites this paper
• Clinical Potential of HER2 and HER3 Imaging in Breast Cancer

  2018cites this paper